Biogen Inc. (BIIB) (BIIB) |
|
321.05 4.1 (1.29%)
|
04-09 16:00 |
|
Open: |
315.1 |
Pre. Close: |
316.95 |
|
High:
|
322.45 |
Low:
|
314.01 |
|
Volume:
|
1,461,861 |
Market Cap:
|
55883M |
|
|
|
|
Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
322.869 - 324.174 |
324.174 - 325.417 |
|
Low:
|
310.776 - 312.218 |
312.218 - 313.592 |
|
Close:
|
318.729 - 321.003 |
321.003 - 323.169 |
|
Technical analysis |
as of: 2020-04-09 4:28:16 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 376.62  One year: 439.89 |
| Support: |
Support1: 285.25 Support2: 262.25 |
| Resistance: |
Resistance1: 322.45 Resistance2: 376.62 |
| Pivot: |
299.48  |
| Moving Average: |
MA(5): 310.22 MA(20): 298.56
MA(100): 301.38 MA(250): 263.24 |
| MACD: |
MACD(12,26): 2.19 Signal(9): -1.01 |
| Stochastic oscillator: |
%K(14,3): 85.33 %D(3): 79.00 |
| RSI: |
RSI(14): 55.79 |
| 52-week: |
High: 374.99 Low: 215.78 Change(%): 36.9 |
| Average Vol(K): |
3-Month: 219604 10-Days: 219952 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.BIIB has closed below upper band by 15.6%. Bollinger Bands are 48.3% wider than normal. The large width of the bands suggest high volatility as compared to BIIB's normal range. The bands have been in this wide range for 1 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
2020-04-09
Sangamo Announces Closing of Biogen Collaboration Agreement
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the closing of its previously announced sale of stock to Biogen Inc. (Nasdaq: BIIB) and that the global licensing collaboration agreement with Biogen for the development and commercialization of gene regulation therapies for Alzheimer’s, Parkinson’s, neuromuscular and other neurological diseases is now effective. Under the terms of the collaboration, Sangamo has received $22
2020-04-09
Biogen Inc (NASDAQ: BIIB) Q4 2019 Earnings Call Transcript | AlphaStreet
Final earnings conference call transcript of Biogen Inc - BIIB stock
|
Financial Analysis |
| Growth |
|
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
